Exposure to Diagnostic Ionizing Radiation in a Population-Based Cohort of Patients with Inflammatory Bowel Disease

2006 ◽  
Vol 101 ◽  
pp. S448-S449 ◽  
Author(s):  
Joanna M. Peloquin ◽  
Darrell S. Pardi ◽  
William J. Sandborn ◽  
Joel G. Fletcher ◽  
Cynthia H. McCollough ◽  
...  
2008 ◽  
Vol 103 (8) ◽  
pp. 2015-2022 ◽  
Author(s):  
Joanna M. Peloquin ◽  
Darrell S. Pardi ◽  
William J. Sandborn ◽  
Joel G. Fletcher ◽  
Cynthia H. McCollough ◽  
...  

2019 ◽  
Vol 25 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Clara Yzet ◽  
Stacy S. Tse ◽  
Maia Kayal ◽  
Robert Hirten ◽  
Jean-Frédéric Colombel

The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.


2013 ◽  
Vol 7 (1) ◽  
pp. 58-69 ◽  
Author(s):  
W. Petritsch ◽  
S. Fuchs ◽  
A. Berghold ◽  
G. Bachmaier ◽  
C. Högenauer ◽  
...  

2018 ◽  
Vol 154 (6) ◽  
pp. S-624
Author(s):  
Han Hee Lee ◽  
Bo-In Lee ◽  
Kang-Moon Lee ◽  
Jin Su Kim ◽  
Jae Myung Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document